Eligibility, any sex, with Opioid Overdose or Drug Overdose. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Cumulative Incidence of Accidental Fatal and Non-Fatal Drug OverdosesPrimary· 0.5 to 2.75 years following intervention, with assessment of primary outcome at 2.75 years
The primary outcome is the cumulative incidence of fatal and non-fatal drug overdoses per 10,000 residents. Fatal overdoses will be defined as drug-related deaths deemed accidental by a state medical examiner. Non-fatal overdoses will be defined as emergency medical services (EMS) runs for suspected non-fatal opioid overdoses identified and classified by the Rhode Island Emergency Medical Services Information System (RI-EMSIS). Since patient outcomes are recorded, patients who did not survive or who were dead upon arrival will be excluded to avoid double-counting.
Group
Value
95% CI
Intervention
43.5
Control
37.1
Number of Participants Engaged in Implementation ActivitiesSecondary· At the time of participation in implementation evaluation activities (surveys, focus groups, or interviews)
Number of staff from participating community-based harm reduction organizations who engaged in implementation evaluation activities, including technical assistance surveys, focus groups, and key informant interviews conducted during the implementation substudy. This outcome reflects participation in implementation evaluation activities conducted as a substudy within the PROVIDENT trial; results are reported as aggregated counts of participants engaged in each activity. Participants may have contributed to more than one implementation activity.
Participants completing implementation surveys
Group
Value
95% CI
Implementation Substudy: Staff at Community-Based Organizations
39
Participants participating in focus groups
Group
Value
95% CI
Implementation Substudy: Staff at Community-Based Organizations
12
Participants participating in key informant interviews
Group
Value
95% CI
Implementation Substudy: Staff at Community-Based Organizations
7
Sponsor's own description
The objectives of this project are to leverage surveillance data to predict future overdose outbreaks, and to evaluate the impact of a randomized, statewide, community-level intervention trial to target overdose prevention programs to neighborhoods at highest risk of future overdose deaths. This study develops and tests an opioid overdose forecasting tool, which will allow other states to identify and deploy interventions to communities at highest risk of opioid-related death. The findings from this study have the potential to significantly improve the allocation of resources to curb the opioid overdose epidemic in the United States.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06429436 — Vending Machine Naloxone Distribution for Your Community (VENDY)
· Phase 4
· recruiting
NCT05877118 — Improving Availability of Intranasal Naloxone
· NA
· recruiting
Other Brown University trials
Trials by the same sponsor.
NCT07502872 — TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-g
· Phase 2
· not yet recruiting
NCT07118618 — Probenecid Administration for Alcohol Craving and Consumption
· Phase 2
· recruiting
NCT07398443 — Using Novel Behavioral Economic Measures to Characterize Dual Marijuana and Tobacco Use in Young Adults
· NA
· recruiting
NCT05901766 — Effect of Iodine-containing Multiple Micronutrient During Lactation on Infant Neurodevelopment
· Phase 4
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brown University
Last refreshed: 9 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05096429.